AAV Transfection Monitoring and Label-Free Analysis of Transfection Efficiency

Every successful AAV therapy begins with a robust cell bank qualification strategy. Strong, viable cells are the foundation for consistent viral yields, and managing cell banks effectively is critical to ensuring quality outcomes. Traditional viability assays only confirm whether cells are alive at a single point in time—alive today but potentially non‑viable tomorrow.

Radiance® takes cell bank qualification a step further by measuring forward‑looking vitality, giving you a clear picture of whether your production cells are strong enough to sustain high yields over time. When you start with healthier, more resilient cells, you naturally set yourself up for better viral vector output. This predictive insight helps reduce batch‑failure risk, keeps viral potency consistent across runs, and makes the entire process more reliable. By focusing on robust cell bank differentiation from the start, manufacturers gain confidence in their starting material and protect the quality of downstream vaccine and gene therapy production.

By placing emphasis on robust cell bank qualification, manufacturers build confidence in their starting material and protect downstream AAV vector quality, scalability, and yields. Predictive cell vitality remains fundamental to any cell‑based production workflow, ensuring that cell banks and cellular starting material are set up for success long before transfection begins. This same principle applies across advanced modalities—from CAR T manufacturing, to stem cell–based therapies, to vaccine potency assays—where sustained cell strength directly influences process reliability and final product yield. No matter the platform, strong, well‑qualified cells are the foundation for consistent performance and successful therapy development.

Once a qualified cell bank is in place, the next step is making sure those cells perform well during transfection—because strong transfection performance is essential for reliable AAV vector production. Bringing real‑time, label‑free transfection monitoring into the process early helps manufacturers choose the right reagents and culture conditions while staying aligned with FDA and EMA expectations for potency and transfection efficiency assays. Taking this proactive approach strengthens process control, supports consistent viral vector quality, and creates a more reliable path from early development through scale‑up and commercial manufacturing.

Radiance® Laser Force Cytology™ makes this even easier by delivering real‑time, label‑free transfection insights that speed up process development and help maintain high yields. Unlike traditional methods such as flow cytometry, ELISA, or ddPCR—which require significant sample prep and long turnaround times—Radiance® provides immediate, actionable data right at the bench, giving teams the clarity they need without the wait.

Beyond transfection monitoring, Radiance® supports broader applications across AAV production. LFC™ enables rapid adventitious agent detection, allowing early identification of contamination and strengthening overall process control. Integrated within PAT frameworks, Radiance® provides continuous monitoring and early intervention to maintain manufacturing integrity.